Proteon Therapeutics’ (NASDAQ:PRTO) “Hold” Rating Reiterated at Cowen and Company
Proteon Therapeutics, Inc. (NASDAQ:PRTO)‘s stock had its “hold” rating restated by equities research analysts at Cowen and Company in a report issued on Tuesday.
Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Proteon Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 17th. Maxim Group set a $6.00 price target on shares of Proteon Therapeutics and gave the stock a “buy” rating in a research note on Thursday, May 4th. Finally, HC Wainwright set a $3.00 price target on shares of Proteon Therapeutics and gave the stock a “hold” rating in a research note on Saturday, May 13th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the stock. Proteon Therapeutics has an average rating of “Hold” and a consensus target price of $8.14.
Shares of Proteon Therapeutics (PRTO) traded down 3.70% on Tuesday, reaching $1.30. 52,550 shares of the company were exchanged. Proteon Therapeutics has a 12 month low of $1.10 and a 12 month high of $11.45. The stock’s market capitalization is $21.80 million. The stock has a 50 day moving average price of $1.38 and a 200-day moving average price of $1.57.
Proteon Therapeutics (NASDAQ:PRTO) last posted its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.11. On average, equities analysts expect that Proteon Therapeutics will post ($1.61) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Proteon Therapeutics’ (NASDAQ:PRTO) “Hold” Rating Reiterated at Cowen and Company” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/08/proteon-therapeutics-nasdaqprto-hold-rating-reiterated-at-cowen-and-company.html.
Proteon Therapeutics Company Profile
Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.
Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.